Competing causes of death and medical comorbidities among patients with human papillomavirus-positive vs human papillomavirus-negative oropharyngeal carcinoma and impact on adherence to radiotherapy

JAMA Otolaryngology - Head and Neck Surgery

Volumn 140, Issue 4, 2014, Pages 312-316

  Hess, Clayton B ^a   Rash, Dominique L ^a   Daly, Megan E ^a   Farwell, D Gregory ^a   Bishop, John ^b   Vaughan, Andrew T ^a   Wilson, Machelle D ^a   Chen, Allen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ADULT; ADVANCED CANCER; AGED; ALCOHOL CONSUMPTION; ANXIETY DISORDER; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANNABIS USE; CAUSE OF DEATH; CHEMORADIOTHERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIFESTYLE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OROPHARYNX CARCINOMA; PAPILLOMAVIRUS INFECTION; PATIENT COMPLIANCE; PREVALENCE; RETROSPECTIVE STUDY; SELF REPORT; TOBACCO USE; WART VIRUS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CAUSE OF DEATH; COMORBIDITY; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PATIENT COMPLIANCE; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84899495050     PISSN: 21686181     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaoto.2013.6732     Document Type: Article

References (24)

1. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100(6):407-420. (Pubitemid 351480511)
2. Dahlstrom KR, Little JA, Zafereo ME, Lung M, Wei Q, Sturgis EM. Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. Head Neck. 2008;30(1):75-84. (Pubitemid 351158324)
3. Yung KC, Piccirillo JF. The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008;134(10):1045-1049.
4. O'Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol. 2012;48(12):1191-1201.
5. Sartor MA, Dolinoy DC, Jones TR, et al. Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics. 2011;6(6):777-787.
6. Wittekindt C, Wagner S, Mayer CS, Klussmann JP. Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2012;11:Doc09.
7. Klussmann JP, Weissenborn SJ, Wieland U, et al. Human papillomavirus-positive tonsillar carcinomas: a different tumor entity? Med Microbiol Immunol. 2003;192(3):129-132. (Pubitemid 37100655)
8. Boscolo-Rizzo P, Del Mistro A, Bussu F, et al. New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital. 2013;33(2):77-87.
9. Psyrri A, Sasaki C, Vassilakopoulou M, Dimitriadis G, Rampias T. Future directions in research, treatment and prevention of HPV-related squamous cell carcinoma of the head and neck. Head Neck Pathol. 2012;6(suppl 1):S121-S128.
10. Brotherston DC, Poon I, Le T, et al. Patient preferences for oropharyngeal cancer treatment de-escalation. Head Neck. 2013;35(2):151-159.
11. Mell LK, Dignam JJ, Salama JK, et al. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010;28(1):15-20.
12. Rose BS, Jeong JH, Nath SK, Lu SM, Mell LK. Population-based study of competing mortality in head and neck cancer. J Clin Oncol. 2011;29(26):3503- 3509.
13. Argiris A, Brockstein BE, Haraf DJ, et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004;10(6):1956-1962. (Pubitemid 38375553)
14. Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007;68(3):654-661. (Pubitemid 46818766)
15. Fesinmeyer MD, Mehta V, Blough D, Tock L, Ramsey SD. Effect of radiotherapy interruptions on survival in Medicare enrollees with local and regional head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010;78(3):675-681.
16. Herrmann T, Baumann M. Prolongation of latency or overall treatment time by unplanned radiation pauses: the clinical importance of compensation [in German]. Strahlenther Onkol. 2005;181(2):65-76. (Pubitemid 40310798)
17. Lindberg RD, Jones K, Garner HH, Jose B, Spanos WJ Jr, Bhatnagar D. Evaluation of unplanned interruptions in radiotherapy treatment schedules. Int J Radiat Oncol Biol Phys. 1988;14(4):811-815.
18. Wyatt RM, Beddoe AH, Dale RG. The effects of delays in radiotherapy treatment on tumour control. Phys Med Biol. 2003;48(2):139-155. (Pubitemid 36204153)
19. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):571-578.
20. Byers RM, Clayman GL, Guillamondequi OM, Peters LJ, Goepfert H. Resection of advanced cervical metastasis prior to definitive radiotherapy for primary squamous carcinomas of the upper aerodigestive tract. Head Neck. 1992;14(2):133-138.
21. Garden AS, Weber RS, Ang KK, Morrison WH, Matre J, Peters LJ. Postoperative radiation therapy for malignant tumors ofminor salivary glands: outcome and patterns of failure. Cancer. 1994;73(10):2563-2569. (Pubitemid 24155534)
22. Bourhis J, Overgaard J, Audry H, et al MARCH Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368(9538):843-854. (Pubitemid 44292807)
23. Baujat B, Bourhis J, Blanchard P, et al MARCH Collaborative Group. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev. 2010;(12):CD002026.
24. Hendry JH, Bentzen SM, Dale RG, et al. A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol (R Coll Radiol). 1996;8(5):297-307. (Pubitemid 26382026)